Rezolute, Inc. (NASDAQ:RZLT) Receives $24.13 Consensus Target Price from Analysts

Rezolute, Inc. (NASDAQ:RZLT) has been given an average rating of “Buy” by the eight ratings firms that are covering the company, Marketbeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have covered the stock in the last year is $24.13.

A number of brokerages recently weighed in on RZLT. JMP Securities reissued a “market outperform” rating and set a $7.00 price objective on shares of Rezolute in a report on Friday, September 20th. Wedbush reissued an “outperform” rating and set a $112.00 price target on shares of Rezolute in a research note on Monday, November 4th. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a research note on Friday, November 8th. Finally, BTIG Research increased their target price on shares of Rezolute from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, September 10th.

Insider Buying and Selling at Rezolute

In other Rezolute news, CFO Daron Evans purchased 10,000 shares of Rezolute stock in a transaction that occurred on Wednesday, December 18th. The shares were bought at an average price of $4.29 per share, for a total transaction of $42,900.00. Following the acquisition, the chief financial officer now directly owns 150,900 shares in the company, valued at approximately $647,361. This trade represents a 7.10 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 18.39% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Rezolute

Large investors have recently made changes to their positions in the business. Jeppson Wealth Management LLC purchased a new stake in Rezolute in the second quarter worth $45,000. Acadian Asset Management LLC lifted its position in shares of Rezolute by 104.2% in the 2nd quarter. Acadian Asset Management LLC now owns 184,502 shares of the company’s stock worth $792,000 after purchasing an additional 94,156 shares during the period. Federated Hermes Inc. boosted its stake in shares of Rezolute by 11.1% during the 2nd quarter. Federated Hermes Inc. now owns 11,279,327 shares of the company’s stock valued at $48,501,000 after purchasing an additional 1,125,000 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of Rezolute during the second quarter valued at about $255,000. Finally, XTX Topco Ltd raised its stake in Rezolute by 205.8% in the second quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock worth $145,000 after buying an additional 22,660 shares in the last quarter. 82.97% of the stock is currently owned by institutional investors.

Rezolute Stock Down 1.0 %

NASDAQ RZLT opened at $4.96 on Friday. The stock’s 50-day simple moving average is $5.10 and its two-hundred day simple moving average is $4.75. Rezolute has a twelve month low of $0.90 and a twelve month high of $6.19. The company has a market capitalization of $287.40 million, a price-to-earnings ratio of -3.91 and a beta of 1.01.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.